What is a Vasorelaxant?
A Vasorelaxant is a substance or means by which tension in the vascular system is reduced, controlled, or eliminated. Vascular tension (high blood pressure) causes headaches, migraines, nausea, and anxiety as result of related pain.
There is a range of Allopathic drugs and therapies designed to reduce vascular tension however in recent years studies have shown that the powerful cannabinoid CBD (Cannabidiol), a natural compound extracted from hemp and cannabis can reduce vascular tension.
A vasorelaxant is a drug or natural substance that causes a reduction in vascular tension.
For almost twenty years, researchers have suggested that endocannabinoids have a major effect on blood vessels. These endocannabinoids cause vasodilation (blood vessel widening) and reduce blood pressure.
Christopher Stanley at the University Of Nottingham School Of Medicine has studied canabinoid receptors. In the study, he and his team activated cannabinoid receptors CB1 and CB2, along with transient receptor potential vanilloid one (TRPV1), peroxisome proliferator-activated receptor gamma (PPARᵧ) and the novel endothelial cannabinoid receptor (CBᶒ). It was observed that, out of all the receptors involved in blood vessel constriction/activation, activation of CB1 receptors on endothelial (blood vessel) tissue helped to reduce stress on vessels that were constricted; this is what happens when vessels dilate and blood pressure reduces. The only instances when CB1 activation didn’t cause vasodilation of all the CB1 receptors was in males and in patients with type –2 diabetes or hypercholesterolemia (high levels of cholesterol).
Of the 34 patients that were used in the study, 27 had cancer and 7 had inflammatory disorder. CBD that was given pre-constricted mesenteric arteries caused a vasorelaxation of 40%. When added to un-contracted arteries, CBD had no effect on baseline tone.
The study showed evidence on the vasorelaxant effects of CBD on human mesenteric arteries that express CB1 activation. This suggested that CB1 is a target for CBD in human mesenteric vessels. A second antagonist (LY320135) was applied to the CB1 receptors, which also found to be an inhibitor of the vasorelaxant response, also indicating CB1 receptor activation in vasorelaxation.
The endocannabinoid receptors proved to be an active component in blood vessel constriction and relaxation. In a constricted vessel, activation of CB1 receptors with CBD caused the vessels to relax and dilate; the desired response to increased blood pressure. The use of CBD can lead the way to providing an alternative and safer treatment for high blood pressure, an often fatal condition.